PPM1N: A Promising Drug Target and Biomarker for Protein Phosphatase 1N

Target Name: PPM1N

NCBI ID: G147699

PPM1N

Other Name(s): probable protein phosphatase 1N | PPM1N_HUMAN | protein phosphatase, Mg2+/Mn2+ dependent 1N (putative) | Protein phosphatase, Mg2+/Mn2+ dependent 1N (putative) | Probable protein phosphatase 1N

PPM1N: A Promising Drug Target and Biomarker for Protein Phosphatase 1N

Introduction

Protein phosphatases are a family of enzymes that regulate protein function by removing phosphate groups from their target proteins. One of the most well-known protein phosphatases is Probable Protein Phosphatase 1N (PPM1N), a protein that plays a critical role in cellular signaling pathways. PPM1N has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

PPM1N Structure and Function

PPM1N is a 21-kDa protein that belongs to the family of protein phosphatases known as cullin-3. PPM1N is primarily localized to the endoplasmic reticulum (ER) and is involved in the regulation of protein kinase C (PKC) activity. PKC is a ubiquitin-protein ligase that regulates various cellular processes, including cell signaling, DNA replication, and cell survival.

PPM1N functions as a negative regulator of PKC by phospho-orylating and ubiquitinating PKC target proteins. PPM1N's catalytic active site is located in the N-terminus of the protein, where it interacts with PKC's alpha-subunit. PPM1N's phospho-orylation sites are located in the tendon Amino acid residue 51 and asparagine residue 64 positions. These sites contribute to PPM1N's specificity for PKC and its ability to regulate PKC activity.

PKC is a well-established drug target and has been implicated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Activation of PKC has been linked to the development and progression of these diseases, and inhibition of PKC has been shown to be therapeutic. Therefore, targeting PPM1N, a critical regulator of PKC activity, may be a promising strategy for the development of new treatments for these diseases.

PPM1N as a Biomarker

PPM1N has also been identified as a potential biomarker for various diseases. One of the main advantages of PPM1N as a biomarker is its high sensitivity to changes in protein phosphorylation levels. PKC is known for its ability to phosphorylate various protein substrates, including transcription factors, Cytoskeletal proteins, and enzymes involved in intracellular signaling pathways. Therefore, changes in PPM1N activity levels can be detected in response to therapeutic interventions or diseases, providing a sensitive readout for the effects of such interventions.

In neurodegenerative disorders, PPM1N has been shown to be involved in the regulation of neurotransmitter release and synaptic plasticity. In addition, changes in PPM1N activity levels have been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Therefore, targeting PPM1N with drugs that modulate its activity may be a promising strategy for the development of new treatments for neurodegenerative disorders.

In cancer, PPM1N has been shown to play a role in the regulation of cell cycle progression and apoptosis. In addition, changes in PPM1N activity levels have been linked to the development and progression of various cancers, including breast, lung, and colorectal cancers. Therefore, targeting PPM1N with drugs that inhibit its activity may be a promising strategy for the development of new treatments for cancer.

In summary, PPM1N is a protein that has been identified as a potential drug target and biomarker for various diseases. Its functions as a negative regulator of PKC and its high sensitivity to changes in protein phosphorylation levels make it an attractive target for therapeutic interventions. Further research is needed to

Protein Name: Protein Phosphatase, Mg2+/Mn2+ Dependent 1N (putative)

The "PPM1N Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPM1N comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets